Ipamorelin Research: GHS-R1a Mechanism, Gut Motility & the Human Trial
Before the details
Here is the Ipamorelin research in plain terms before the numbers pile up. Ipamorelin is a five-amino-acid peptide that switches on the ghrelin receptor — the docking point your body's natural hunger hormone uses. That receptor sits in two useful places: the gland that releases growth hormone, and the nerves that move your gut. So ipamorelin does two things in studies: it releases a short, clean pulse of growth hormone (clean because it leaves stress and milk hormones mostly alone), and it speeds up a sluggish gut. The growth-hormone story is solid in animals and was measured once in humans. The gut story is solid in rats but failed the one human test it got. Half the drug is gone from the blood in about two hours. Below, each claim is tied to the study that measured it.
The selectivity finding that defined the molecule
Ipamorelin's signature was established in one paper. In rat pituitary cells, anaesthetised rats, and conscious swine, it released GH potently — swine ED50 of 2.3 ± 0.03 nmol/kg, against 3.9 nmol/kg for GHRP-6 — while leaving ACTH and cortisol at GHRH-baseline levels even at doses more than 200-fold above the GH ED50 [1]. That is the whole point of the compound: earlier growth-hormone-releasing peptides (GHRP-6, GHRP-2) also raised stress and milk hormones; ipamorelin separated the GH signal from the rest. It does so through GHS-R1a (the ghrelin receptor) on pituitary somatotrophs, a pathway distinct from and complementary to GHRH — which is the entire rationale for pairing it with a GHRH analog [1].
Gut motility: the mechanism that sent it to a clinical trial
The GHS-R1a receptor is not confined to the pituitary; it sits on enteric and vagal neurons, and that is where ipamorelin's prokinetic story lives. In a surgical rat model of postoperative ileus, IV ipamorelin at 0.014 and 0.14 μmol/kg accelerated gastric emptying back toward non-operated control levels, with the mechanism confirmed in vitro at roughly 1 μM as ghrelin-receptor/cholinergic activation [8]. In a separate rat ileus model, repetitive IV ipamorelin (0.1 or 1 mg/kg four times daily) significantly increased cumulative fecal output, food intake, and body-weight gain over 48 hours, and a single dose shortened time to first bowel movement [7].
The broader class supports the rationale. Ghrelin's prokinetic actions — faster gastric emptying, higher gastric tone, stronger migrating motor complexes — are well reviewed [9][12]. The structurally related agonist TZP-101 reversed surgery- and morphine-induced transit delay in rats [13] and decreased time to first bowel movement while raising fecal output, the first demonstration of a ghrelin agonist improving large-bowel function in postoperative ileus [14]. Mechanistic work even suggests GHRPs partly act by triggering endogenous ghrelin release from the gastric mucosa: gastric resection cut GHRP-6-induced GH release by 60-70% but left GHRH-induced release intact [11].
Human pharmacokinetics: a single clean pulse, ~2-hour half-life
One of the only human ipamorelin datasets comes from a population PK/PD study in healthy male volunteers (n=8 per dose level; five 15-minute IV infusions of 4.21-140.45 nmol/kg) [2]. The kinetics were dose-proportional: terminal half-life approximately 2 hours, clearance 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg. The GH response was a single discrete pulse peaking at about 0.67 h (40 minutes) after dosing [2]. In rats, plasma clearance is roughly 5-fold lower than GHRP-6. These numbers are the backbone of any honest discussion of timing — and they are human, which most ipamorelin data is not.
Is ipamorelin fda approved
No. Ipamorelin is not FDA-approved for any indication and has never been approved as a drug by any regulatory authority. It was investigated for postoperative ileus (NCT00672074) but never approved [3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list following nominator withdrawal, and reviewed both the acetate and free base at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting — it is not an approved bulk substance for compounding. It is marketed only as a research chemical, and it is prohibited in sport at all times under WADA category S2.
The human efficacy anchor: the Phase 2 trial that missed
The defining human result is a negative one. The only published Phase 2 RCT (NCT00672074) enrolled 114 adults undergoing bowel resection, given 0.03 mg/kg IV twice daily for up to 7 days [3]. It missed its primary endpoint: median time to first tolerated meal was 25.3 h with ipamorelin versus 32.6 h with placebo (p=0.15). Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo — no ipamorelin-specific safety signal in that short perioperative window, but no demonstrated efficacy either [3]. A 2026 structured narrative review of injectable peptides in sports medicine reached a consistent conclusion: ipamorelin remains an investigational GH-axis secretagogue with no reproducible human evidence for musculoskeletal outcomes, and use should be confined to rigorous research protocols [18]. The honest read of the human record is that efficacy has not been shown for any tested indication.
The freshest finding: a 2024 cachexia model
The most recent published in-vivo ipamorelin study is a 2024 ferret experiment. Intraperitoneal ipamorelin (1-3 mg/kg) inhibited cisplatin-induced body-weight loss by approximately 24% on the last day of the delayed phase (48-72 h) — but had no anti-emetic effect on either acute or delayed emesis, in contrast to central anamorelin, which cut acute emesis by 60% [5]. The takeaway is specific: ipamorelin defended weight through a peripheral mechanism without touching nausea. It is the freshest and most defensible recent data point, and it keeps the appetite/weight story anchored to a real model rather than marketing.